EpistaxisNCT06836102
Usage of Orange Peel Extract in Management of Epistaxis
A study testing Orange in people with Epistaxis, run by Minia University.
Trial summary
Efficacy of orange peel extract in treatment of epistaxis in children Read more about this study
- Who is it for?
- Ages 5 to 15 years
- Conditions the study is for
- Epistaxis
- What is being tested?
- Orange
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- Feb 2025to May 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 15 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- children with anterior epistaxis from little's area
Who cannot join
- patient with nasal polyp.
- patients with hematological abnormalities.
- patients with general diseases affecting coagulation system.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Hanaa Bahaa El-khouly, consultant of pharmacognosy contact
About this study
Official title: The Potential of Nano-based Gel of Orange Peel Extract in Management of Epistaxis : a Randomized Double Blind Clinical Study
Efficacy of orange peel extract in treatment of epistaxis in children
Read the detailed description
Formulation of orange peel extract into gel substance and usage of it in local treatment of epistaxis
- Conditions
- Epistaxis
- Being tested
- Orange
- Medical subject headings
- Epistaxis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OrangeDietary supplement
usage of orange peel extract in gel layer in treatment of epistaxis
| Study group | Role | What they receive |
|---|---|---|
| gel of Orange peel extract | Active comparator | usage of gel of Orange peel extract as a local treatment of epistaxis Receives: Dietary Supplement: Orange |
| nano-based gel of Orange peel extract | Active comparator | usage of nano-based gel of Orange peel extract as a local treatment of epistaxis Receives: Dietary Supplement: Orange |
| placebo | Placebo comparator | usage of placebo in control cases Receives: Dietary Supplement: Orange |
What is being measured
The primary outcome is the main question the study is designed to answer.
The potential of nano-based gel of Orange peel extract in management of epistaxis
assessment of epistaxis ( amount, severity and frequency ) according to ESS ( Epistaxis Severity Score ) between patients in study groups
Measured: From enrollment to the end of treatment at 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2025
- Study startFeb 2025 (estimated)
- Primary completionApr 2025 (estimated)
- Study completionMay 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for EpistaxisStudies of the same condition, open and under way.
- More trials run by Minia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Minia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mostafa Nasr Zayed, Minia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06836102
- Sponsor's protocol ID
- orange peel in epistaxis
- Status last verified
- Feb 2025
- First submitted
- 15 Feb 2025
- Last updated
- 20 Feb 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: result
Publications
Andrade MA, Barbosa CH, Shah MA, Ahmad N, Vilarinho F, Khwaldia K, Silva AS, Ramos F. Citrus By-Products: Valuable Source of Bioactive Compounds for Food Applications. Antioxidants (Basel). 2022 Dec 25;12(1):38. doi: 10.3390/antiox12010038.
PubMed 36670900
Study at a glance
From the registry record, last updated by the sponsor on 20 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Potential of Nano-based Gel of Orange Peel Extract in Management of Epistaxis : a Randomized Double Blind Clinical Study
- ClinicalTrials.gov ID
- NCT06836102
- Acronym / sponsor ID
- orange peel in epistaxis
- Conditions
- Epistaxis
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Minia UniversityUniversity, hospital or other
- Study start
- Feb 2025 (estimated)
- Primary completion
- Apr 2025 (estimated)
- Study completion
- May 2025 (estimated)
- First posted
- 20 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Efficacy of orange peel extract in treatment of epistaxis in children
Detailed description
Formulation of orange peel extract into gel substance and usage of it in local treatment of epistaxis
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| gel of Orange peel extract | Active comparator | Dietary Supplement: Orangeusage of gel of Orange peel extract as a local treatment of epistaxis |
| nano-based gel of Orange peel extract | Active comparator | Dietary Supplement: Orangeusage of nano-based gel of Orange peel extract as a local treatment of epistaxis |
| placebo | Placebo comparator | Dietary Supplement: Orangeusage of placebo in control cases |
Who may qualify
- Ages
- 5 to 15 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- children with anterior epistaxis from little's area
Key exclusion criteria (3 listed)
- patient with nasal polyp.
- patients with hematological abnormalities.
- patients with general diseases affecting coagulation system.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Orangeusage of orange peel extract in gel layer in treatment of epistaxis | Dietary supplement | gel of Orange peel extract, nano-based gel of Orange peel extract, placebo |
Primary outcome
The potential of nano-based gel of Orange peel extract in management of epistaxis
Time frame: From enrollment to the end of treatment at 4 weeks
assessment of epistaxis ( amount, severity and frequency ) according to ESS ( Epistaxis Severity Score ) between patients in study groups
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Feb 2025.
- Background: PubMed 36670900Andrade MA, Barbosa CH, Shah MA, Ahmad N, Vilarinho F, Khwaldia K, Silva AS, Ramos F. Citrus By-Products: Valuable Source of Bioactive Compounds for Food Applications. Antioxidants (Basel). 2022 Dec 25;12(1):38. doi: 10.3390/antiox12010038.
- Epistaxis: Outpatient ManagementLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. result
Related trials for Epistaxis
Not yet recruitingPhase 1
Topical TOR-582 Treatment of Epistaxis in HHT
Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Active, not recruitingPhase 1/2
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia
Not yet recruitingPhase 2
Effect of Vitamin C Administration on Intraoperative Bleeding in Patients Undergoing Sinusoscopy
Chronic Rhinosinusitis, Intraoperative Bleeding
Recruiting
Comparative Study - Transseptal Suture Technique Verses Anterior Nasal Packing After Septoplasty
Deviated Nasal Septum, Postoperative Nasal Pain
RecruitingPhase 3
RADA16 for Adult Tonsillectomy
Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hanaa Bahaa El-khouly, consultant of pharmacognosy contact
Questions about this trial
What is this clinical trial studying?
A study testing Orange in people with Epistaxis, run by Minia University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mostafa Nasr Ahmed, consultant (+201007905656, drmostafanasr1988@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The potential of nano-based gel of Orange peel extract in management of epistaxis (time frame: From enrollment to the end of treatment at 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06836102, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2025.